Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
3 drugs in development
By Therapeutic Area
top 4
R&D Momentum
60/100
Pipeline Velocity
19/100
Trial Completion Rate
92/100
Pipeline Concentration
22/100
Pipeline Freshness
0/100
Strategic Signals
Activity
Last 14 days
The Natural History, Physiology, Microbiome and Biochemistry Studies of Propionic Acidemia
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
Genomic Sequencing for Evaluation of Uncommon Disease Manifestations Through the Childhood Complex Disease Genomic Section
Deciphering the Genetic Architecture of Autoimmune Diseases
Observational Study of Advanced Data Analytics in Genetic Conditions
The Phenotype and Etiology of Proteus Syndrome
Genomic Services Research Program
Investigations Into Chediak-Higashi Syndrome and Related Disorders
Diagnosis and Treatment of Patients With Inborn Errors of Metabolism or Other Genetic Disorders
Clinical and Basic Investigations of Methylmalonic Acidemia (MMA) and Related Disorders
An Exploratory Study of the Genetics, Pathophysiology, and Natural History of Autoinflammatory Diseases
Insights Into Microbiome and Environmental Contributions to Sickle Cell Disease and Leg Ulcers
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)